2009 Schering-Plough Excellence Award for WuXi PharmaTech

WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company, with operations in China and the United States, today announced that it had received the 2009 Excellence Award from Schering-Plough.

The award recognizes WuXi's contributions to Schering-Plough's success in a range of research projects, from the creation of compound libraries to medicinal chemistry. The partnership has grown in size and scope from a handful of employees four years ago to a large, multidisciplinary team today. WuXi has consistently exceeded Schering-Plough's expectations and earned high customer satisfaction ratings. By developing a comprehensive internal training system, implementing efficient project management, and kindling a collaborative team spirit, the WuXi team has overcome numerous hurdles.

"We are pleased and honored to receive this award from Schering-Plough in recognition of the efforts of our talented and dedicated team of scientists," commented Dr. Ge Li, Chairman and CEO of WuXi AppTec. "Commitment to excellent customer service drives everything we do."

SOURCE WuXi PharmaTech (Cayman) Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research links COVID-19 vaccines to temporary facial palsy in over 5,000 patients